Loading clinical trials...
Loading clinical trials...
Phase 2 Study of Paclitaxel (NSC #673089) + Ipatasertib (NSC #781451) in Taxane-Refractory Participants With PTEN/AKT-Altered Advanced Non-Breast Solid Tumors: A ComboMATCH Treatment Trial
Conditions
Interventions
Biopsy Procedure
Biospecimen Collection
+4 more
Locations
210
United States
University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States
University of South Alabama Mitchell Cancer Institute
Mobile, Alabama, United States
Alaska Women's Cancer Care
Anchorage, Alaska, United States
Kingman Regional Medical Center
Kingman, Arizona, United States
PCR Oncology
Arroyo Grande, California, United States
UC San Diego Moores Cancer Center
La Jolla, California, United States
Start Date
September 22, 2023
Primary Completion Date
August 31, 2026
Completion Date
August 31, 2026
Last Updated
April 13, 2026
NCT04879121
NCT04693377
NCT03907475
NCT06500455
NCT05372640
NCT04550494
Lead Sponsor
National Cancer Institute (NCI)
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions